Paper Details

  1. Home
  2. Paper Details

Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial.

Author: CreutzigUrsula, DworzakMichael, KlusmannJan-Henning, RascheMareike, ReinhardtDirk, SchweitzerJana, ZimmermannMartin, von NeuhoffChristine

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

While treatment for children with acute megakaryoblastic leukemia (AMKL) has improved, there are still uncertainties about the best treatment and who is at higher risk. This study examined 97 children with AMKL and found that their survival rate was lower (60%) compared to other types of leukemia (68%). While survival rates improved in more recent treatment groups, stem cell transplants didn't significantly improve survival. Certain genetic changes were associated with better or worse outcomes, but the best predictor of success was how well the child responded to initial treatment. AMKL remains a challenging form of leukemia for children, but new treatments have significantly increased survival rates.
Paper Details　
Original Abstract of the Article :
Despite recent advances in the treatment of children with acute megakaryoblastic leukemia (AMKL) using intensified treatment protocols, clear prognostic indicators, and treatment recommendations for this acute myeloid leukemia (AML) subgroup are yet to be defined. Here, we report the outcome of 97 p...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488462/

データ提供：米国国立医学図書館（NLM）

Acute Megakaryoblastic Leukemia: Navigating the Shifting Sands of Pediatric Cancer

The vast desert of childhood cancer is a harsh and unforgiving landscape. Acute megakaryoblastic leukemia (AMKL) poses a significant challenge, with its unpredictable nature and often challenging treatment outcomes. This research, focusing on the AML-BFM 04 trial, takes us on a journey through the shifting sands of this pediatric cancer, seeking to shed light on improved treatment strategies.

The authors meticulously analyze the data from 97 pediatric patients with de novo AMKL, revealing a complex picture. While the 5-year overall survival remained lower than other AML subgroups, the AML-BFM 04 trial demonstrated a significant improvement compared to previous treatment regimens. Interestingly, the presence of a gain of chromosome 21 was associated with superior survival, while translocation t(1;22)(p13;q13) was linked to poorer event-free survival. However, the study emphasizes that treatment response remains the most crucial prognostic indicator.

A Beacon of Hope in the Desert: Improved Outcomes in AMKL

This research provides a glimmer of hope in the desert of pediatric cancer. The improved outcomes observed in the AML-BFM 04 trial demonstrate the power of scientific innovation and the importance of tailored treatment approaches. It offers encouragement to families facing this daunting diagnosis, emphasizing that progress is being made.

Navigating the Desert of Cancer Treatment: Personalized Strategies for AMKL

This study highlights the need for personalized strategies in cancer treatment. The authors emphasize the importance of monitoring treatment response and adapting therapies based on individual patient characteristics and genetic profiles. This approach allows for a more precise and effective navigation through the desert of cancer treatment.

Dr. Camel's Conclusion

This study reminds us that even in the harsh desert of childhood cancer, there are oases of hope. The authors' research provides valuable insights into AMKL, guiding us towards better treatment strategies and improving the chances of survival for our youngest patients. Their journey through the shifting sands of pediatric oncology offers a beacon of hope for families facing this challenging diagnosis.

Date :
  1. Date Completed 2015-09-09
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

25913479

DOI: Digital Object Identifier

PMC4488462

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.